Provided by Tiger Fintech (Singapore) Pte. Ltd.

Milestone Pharmaceuticals Inc.

1.88
-0.0100-0.53%
Post-market: 1.900.0200+1.06%19:59 EDT
Volume:1.46M
Turnover:2.74M
Market Cap:159.79M
PE:-2.24
High:1.93
Open:1.91
Low:1.86
Close:1.89
52wk High:2.75
52wk Low:0.6254
Shares:84.99M
Float Shares:78.81M
Volume Ratio:0.88
T/O Rate:1.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8376
EPS(LYR):-0.6674
ROE:-780.29%
ROA:-50.33%
PB:-9.00
PE(LYR):-2.82

Loading ...

Milestone Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 14

BRIEF-Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results

Reuters
·
May 14

Milestone Pharmaceuticals Q1 EPS $(0.31) Misses $(0.18) Estimate

Benzinga
·
May 14

Milestone Pharmaceuticals Inc expected to post a loss of 18 cents a share - Earnings Preview

Reuters
·
May 09

Milestone Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Apr 02

BUZZ-Milestone Pharma falls after TD Cowen downgrades to "hold", removes PT

Reuters
·
Apr 01

HC Wainwright Adjusts Price Target on Milestone Pharmaceuticals to $10 From $25, Maintains Buy Rating

MT Newswires Live
·
Apr 01

TD Cowen Downgrades Milestone Pharmaceuticals to Hold From Buy

MT Newswires Live
·
Apr 01

BUZZ-U.S. STOCKS ON THE MOVE-GameStop, Oxford Industries, Wolfspeed

Reuters
·
Mar 29

Milestone Pharmaceuticals Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 29

Dow Tumbles Over 500 Points; Abacus Global Management Shares Spike Higher

Benzinga
·
Mar 29

Piper Sandler Adjusts Price Target on Milestone Pharmaceuticals to $4 From $5, Maintains Overweight Rating

MT Newswires Live
·
Mar 28

BRIEF-FDA Issues Complete Response Letter For Etripamil For PSVT

Reuters
·
Mar 28

BUZZ-Milestone Pharma slumps after FDA declines to approve heart rhythm nasal spray

Reuters
·
Mar 28

FDA Rejects Milestone Pharmaceuticals' Etripamil Nasal Spray

Dow Jones
·
Mar 28

US FDA declines to approve Milestone Pharma's heart rhythm nasal spray

Reuters
·
Mar 28